ConductScience.org, home
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
API referenceFor AI assistants

Trial · NCT02193074

Results by group130

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 130

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Motor Milestones RespondersControl0percentage of participants
Percentage of Motor Milestones RespondersNusinersen51percentage of participants
Time to Death or Permanent VentilationControlBy Day 91 (13 weeks/3 months)0.268proportion of participants
Time to Death or Permanent VentilationNusinersenBy Day 91 (13 weeks/3 months)0.240proportion of participants
Time to Death or Permanent VentilationControlBy Day 182 (26 weeks/6 months)0.605proportion of participants
Time to Death or Permanent VentilationNusinersenBy Day 182 (26 weeks/6 months)0.294proportion of participants
Time to Death or Permanent VentilationControlBy Day 273 (39 weeks/9 months)0.702proportion of participants
Time to Death or Permanent VentilationNusinersenBy Day 273 (39 weeks/9 months)0.404proportion of participants
Time to Death or Permanent VentilationControlBy Day 364 (52 weeks/12 months)0.735proportion of participants
Time to Death or Permanent VentilationNusinersenBy Day 364 (52 weeks/12 months)0.447proportion of participants
Time to Death or Permanent VentilationControlBy Day 394 (13 months)0.735proportion of participants
Time to Death or Permanent VentilationNusinersenBy Day 394 (13 months)0.447proportion of participants
Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) RespondersControl3percentage of participants
Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) RespondersNusinersen71percentage of participants
Summary of Time to DeathControlby Day 910.195proportion of particiants
Summary of Time to DeathNusinersenby Day 910.101proportion of particiants
Summary of Time to DeathControlby Day 1820.348proportion of particiants
Summary of Time to DeathNusinersenby Day 1820.141proportion of particiants
Summary of Time to DeathControlby Day 2730.382proportion of particiants
Summary of Time to DeathNusinersenby Day 2730.173proportion of particiants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02193074/results

API referenceFor AI assistants